JP Morgan Chase
KURA icon

JP Morgan Chase’s Kura Oncology KURA Stock Holding History

JP Morgan Chase’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Buy
52,572
+12,471
+31% +$107K ﹤0.01% 5144
2025
Q4 		$417K Buy
40,101
+6,065
+18% +$63.6K ﹤0.01% 5144
2025
Q3 		$301K Sell
34,036
-58,655
-63% -$418K ﹤0.01% 5299
2025
Q2 		$535K Sell
92,691
-256,326
-73% -$1.57M ﹤0.01% 4740
2025
Q1 		$2.3M Sell
349,017
-16,904
-5% -$132K ﹤0.01% 3773
2024
Q4 		$3.19M Sell
365,921
-43,320
-11% -$623K ﹤0.01% 3782
2024
Q3 		$8M Buy
409,241
+3,092
+0.8% +$62.7K ﹤0.01% 2809
2024
Q2 		$8.36M Sell
406,149
-28,247
-7% -$581K ﹤0.01% 2605
2024
Q1 		$9.27M Sell
434,396
-38,596
-8% -$750K ﹤0.01% 2560
2023
Q4 		$6.8M Sell
472,992
-8,877
-2% -$87.3K ﹤0.01% 2823
2023
Q3 		$4.39M Sell
481,869
-20,582
-4% -$209K ﹤0.01% 2929
2023
Q2 		$5.32M Sell
502,451
-10,771
-2% -$127K ﹤0.01% 2810
2023
Q1 		$6.28M Sell
513,222
-691
-0.1% -$8.62K ﹤0.01% 2643
2022
Q4 		$6.38M Sell
513,913
-34,721
-6% -$505K ﹤0.01% 2629
2022
Q3 		$7.5M Sell
548,634
-12,966
-2% -$200K ﹤0.01% 2394
2022
Q2 		$10.3M Buy
561,600
+480,848
+595% +$6.92M ﹤0.01% 2130
2022
Q1 		$1.3M Sell
80,752
-25,308
-24% -$365K ﹤0.01% 4082
2021
Q4 		$1.49M Buy
106,060
+50,547
+91% +$819K ﹤0.01% 4072
2021
Q3 		$1.04M Sell
55,513
-1,490
-3% -$28.1K ﹤0.01% 4281
2021
Q2 		$1.19M Buy
57,003
+3,477
+6% +$86.3K ﹤0.01% 4181
2021
Q1 		$1.51M Sell
53,526
-35,123
-40% -$1.11M ﹤0.01% 3907
2020
Q4 		$2.9M Buy
88,649
+50,549
+133% +$1.78M ﹤0.01% 3226
2020
Q3 		$1.16M Buy
38,100
+327
+0.9% +$7.22K ﹤0.01% 3560
2020
Q2 		$616K Buy
37,773
+4,162
+12% +$60K ﹤0.01% 3760
2020
Q1 		$335K Sell
33,611
-26,267
-44% -$301K ﹤0.01% 4036
2019
Q4 		$823K Buy
59,878
+22,577
+61% +$335K ﹤0.01% 3979
2019
Q3 		$566K Buy
37,301
+3,890
+12% +$69.2K ﹤0.01% 4116
2019
Q2 		$661K Buy
33,411
+26,508
+384% +$440K ﹤0.01% 4090
2019
Q1 		$115K Sell
6,903
-325
-4% -$5.01K ﹤0.01% 4840
2018
Q4 		$101K Buy
7,228
+675
+10% +$8.94K ﹤0.01% 4848
2018
Q3 		$115K Buy
6,553
+1,506
+30% +$28.9K ﹤0.01% 4894
2018
Q2 		$92K Buy
5,047
+715
+17% +$12.1K ﹤0.01% 4869
2018
Q1 		$81K Sell
4,332
-723
-14% -$14.1K ﹤0.01% 4662
2017
Q4 		$78K Sell
5,055
-50,416
-91% -$743K ﹤0.01% 4752
2017
Q3 		$802K Buy
+55,471
New +$521K ﹤0.01% 3625

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's KURA Position: Q1 2026 in Review

JP Morgan Chase increased its Kura Oncology (KURA) stake by 31% in Q1 2026, buying an estimated $107K and bringing the position to 52,572 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #5144.

JP Morgan Chase first reported a position in KURA in Q3 2017 and has held it in 35 quarters since. The position peaked at $10.3M in Q2 2022. 220 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • JP Morgan Chase held 52,572 shares of Kura Oncology worth $406K as of Q1 2026.
  • JP Morgan Chase bought 12,471 Kura Oncology shares in Q1 2026, an estimated $107K.
  • Kura Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5144 holding.
  • JP Morgan Chase first reported a position in Kura Oncology in Q3 2017 and has held it in 35 quarters since.
  • JP Morgan Chase's Kura Oncology position peaked at $10.3M in Q2 2022.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.